Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels

Jakub Tolar, H. Joachim Deeg, Sally Arai, Mitchell Horwitz, Joseph H. Antin, John M. McCarty, Roberta H. Adams, Marian Ewell, Eric S. Leifer, Iris D. Gersten, Shelly L. Carter, Mary M. Horowitz, Ryotaro Nakamura, Michael A. Pulsipher, Nancy L. DiFronzo, Dennis L. Confer, Mary Eapen, Paolo Anderlini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine, and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY dose level 150 mg/kg was closed due to excessive organ toxicity (n = 6) or viral pneumonia (n = 1), resulting in the death of 7 of 14 patients. CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m2), and antithymocyte globulin was associated with excessive organ toxicity.

Original languageEnglish (US)
Pages (from-to)1007-1011
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number7
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Transplantation Conditioning
Unrelated Donors
Aplastic Anemia
Cyclophosphamide
Bone Marrow
Antilymphocyte Serum
Whole-Body Irradiation
Viral Pneumonia
Bone Marrow Transplantation
fludarabine
Transplants

Keywords

  • Antithymocyte globulin
  • Bone marrow transplantation
  • Matched unrelated donor
  • Stem cell transplantation

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia : Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. / Tolar, Jakub; Deeg, H. Joachim; Arai, Sally; Horwitz, Mitchell; Antin, Joseph H.; McCarty, John M.; Adams, Roberta H.; Ewell, Marian; Leifer, Eric S.; Gersten, Iris D.; Carter, Shelly L.; Horowitz, Mary M.; Nakamura, Ryotaro; Pulsipher, Michael A.; DiFronzo, Nancy L.; Confer, Dennis L.; Eapen, Mary; Anderlini, Paolo.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 7, 07.2012, p. 1007-1011.

Research output: Contribution to journalArticle

Tolar, J, Deeg, HJ, Arai, S, Horwitz, M, Antin, JH, McCarty, JM, Adams, RH, Ewell, M, Leifer, ES, Gersten, ID, Carter, SL, Horowitz, MM, Nakamura, R, Pulsipher, MA, DiFronzo, NL, Confer, DL, Eapen, M & Anderlini, P 2012, 'Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels', Biology of Blood and Marrow Transplantation, vol. 18, no. 7, pp. 1007-1011. https://doi.org/10.1016/j.bbmt.2012.04.014
Tolar, Jakub ; Deeg, H. Joachim ; Arai, Sally ; Horwitz, Mitchell ; Antin, Joseph H. ; McCarty, John M. ; Adams, Roberta H. ; Ewell, Marian ; Leifer, Eric S. ; Gersten, Iris D. ; Carter, Shelly L. ; Horowitz, Mary M. ; Nakamura, Ryotaro ; Pulsipher, Michael A. ; DiFronzo, Nancy L. ; Confer, Dennis L. ; Eapen, Mary ; Anderlini, Paolo. / Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia : Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 7. pp. 1007-1011.
@article{bf9933e0a9e44f23be3ea777ac44aa8c,
title = "Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels",
abstract = "Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine, and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY dose level 150 mg/kg was closed due to excessive organ toxicity (n = 6) or viral pneumonia (n = 1), resulting in the death of 7 of 14 patients. CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m2), and antithymocyte globulin was associated with excessive organ toxicity.",
keywords = "Antithymocyte globulin, Bone marrow transplantation, Matched unrelated donor, Stem cell transplantation",
author = "Jakub Tolar and Deeg, {H. Joachim} and Sally Arai and Mitchell Horwitz and Antin, {Joseph H.} and McCarty, {John M.} and Adams, {Roberta H.} and Marian Ewell and Leifer, {Eric S.} and Gersten, {Iris D.} and Carter, {Shelly L.} and Horowitz, {Mary M.} and Ryotaro Nakamura and Pulsipher, {Michael A.} and DiFronzo, {Nancy L.} and Confer, {Dennis L.} and Mary Eapen and Paolo Anderlini",
year = "2012",
month = "7",
doi = "10.1016/j.bbmt.2012.04.014",
language = "English (US)",
volume = "18",
pages = "1007--1011",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia

T2 - Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels

AU - Tolar, Jakub

AU - Deeg, H. Joachim

AU - Arai, Sally

AU - Horwitz, Mitchell

AU - Antin, Joseph H.

AU - McCarty, John M.

AU - Adams, Roberta H.

AU - Ewell, Marian

AU - Leifer, Eric S.

AU - Gersten, Iris D.

AU - Carter, Shelly L.

AU - Horowitz, Mary M.

AU - Nakamura, Ryotaro

AU - Pulsipher, Michael A.

AU - DiFronzo, Nancy L.

AU - Confer, Dennis L.

AU - Eapen, Mary

AU - Anderlini, Paolo

PY - 2012/7

Y1 - 2012/7

N2 - Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine, and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY dose level 150 mg/kg was closed due to excessive organ toxicity (n = 6) or viral pneumonia (n = 1), resulting in the death of 7 of 14 patients. CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m2), and antithymocyte globulin was associated with excessive organ toxicity.

AB - Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine, and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY dose level 150 mg/kg was closed due to excessive organ toxicity (n = 6) or viral pneumonia (n = 1), resulting in the death of 7 of 14 patients. CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m2), and antithymocyte globulin was associated with excessive organ toxicity.

KW - Antithymocyte globulin

KW - Bone marrow transplantation

KW - Matched unrelated donor

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84862131215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862131215&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.04.014

DO - 10.1016/j.bbmt.2012.04.014

M3 - Article

C2 - 22546497

AN - SCOPUS:84862131215

VL - 18

SP - 1007

EP - 1011

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -